IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 244 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $288,415 | -22.9% | 63,388 | +19.4% | 0.00% | -33.3% |
| Q2 2023 | $373,866 | +78.4% | 53,106 | +54.8% | 0.00% | +50.0% |
| Q1 2023 | $209,579 | -1.8% | 34,301 | +2.7% | 0.00% | 0.0% |
| Q4 2022 | $213,394 | -30.5% | 33,395 | +4.3% | 0.00% | -33.3% |
| Q3 2022 | $307,000 | -13.0% | 32,033 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $353,000 | -37.5% | 31,945 | -5.9% | 0.00% | -40.0% |
| Q1 2022 | $565,000 | -11.3% | 33,930 | +1.6% | 0.01% | 0.0% |
| Q4 2021 | $637,000 | -22.4% | 33,381 | +0.2% | 0.01% | -28.6% |
| Q3 2021 | $821,000 | -1.3% | 33,308 | +4.2% | 0.01% | 0.0% |
| Q2 2021 | $832,000 | -17.9% | 31,962 | -0.2% | 0.01% | -22.2% |
| Q1 2021 | $1,014,000 | -31.4% | 32,026 | +0.5% | 0.01% | -30.8% |
| Q4 2020 | $1,478,000 | +38.3% | 31,852 | -1.9% | 0.01% | +18.2% |
| Q3 2020 | $1,069,000 | +60.8% | 32,459 | +33.9% | 0.01% | +22.2% |
| Q2 2020 | $665,000 | -11.8% | 24,241 | -3.7% | 0.01% | -30.8% |
| Q1 2020 | $754,000 | – | 25,182 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |